Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04670770

An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

Neuromyelitis Optica Spectrum Disorders Clinical Trial

Official title:
An Open Label Phase II Clinical Trial Evaluating the Efficacy and Safety of SHR1459 in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)

Clinical Trial Summary

This is an open-label study, to evaluate the efficacy and safety of SHR1459 in participants with NMOSDs.

Clinical Trial Description

Therefore, the investigators of this study are investigating whether SHR1459 could prevent relapse of NMOSDs. The primary objective of this study is to evaluate the effectiveness of SHR1459 in NMOSDs patients. The secondary objectives are to determine: The safety profile of SHR 1459 in patients with NMOSDs. Whether SHR1459 reduce MRI lesions and APQ4-Abs level. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04670770
Study type Interventional
Source Reistone Biopharma Company Limited
Contact
Status Completed
Phase Phase 2
Start date January 20, 2021
Completion date August 15, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02836327 - Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders N/A
Recruiting NCT04146285 - A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders Phase 1
Not yet recruiting NCT06068829 - Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
Recruiting NCT05204459 - MS-ResearchBiomarkerS
Completed NCT03350633 - Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Completed NCT04388072 - An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit
Completed NCT05871658 - Efficacy of Electroacupuncture in NMOSD Patients With Pain: Study Protocol N/A
Recruiting NCT02021825 - Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Phase 4
Recruiting NCT06249438 - A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy Phase 1
Not yet recruiting NCT06413654 - A Phase II/III Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) Phase 2/Phase 3
Recruiting NCT03330418 - A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Phase 3
Enrolling by invitation NCT04101058 - Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders
Enrolling by invitation NCT02809079 - Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Phase 4
Recruiting NCT02889965 - The French Multiple Sclerosis Registry N/A
Completed NCT02850705 - The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)
Not yet recruiting NCT06212245 - A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Phase 4
Completed NCT03062579 - A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Phase 1/Phase 2
Recruiting NCT05730699 - Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) Phase 3